Tuberculosis has reclaimed its position as the world’s deadliest infectious disease, with global diagnoses reaching record levels in consecutive years and U.S. case counts climbing to their highest point since 2011. The World Health Organization and the U.S. Centers for Disease Control and Prevention are both reporting sustained increases that have reversed decades of progress, driven by pandemic-era disruptions, shifting migration patterns, and funding shortfalls that threaten to stall the response further.
Record Global Diagnoses Mask Deeper Problems
The WHO recorded 8.2 million newly diagnosed TB cases worldwide in 2023, the highest single-year total the agency has ever reported. That record did not hold long. Global diagnoses rose again in 2024, eclipsing the prior year’s total and keeping TB among the top causes of death worldwide.
On the surface, higher diagnosis numbers could signal better detection rather than worsening spread. More people found and treated should, in theory, reduce transmission over time. But the WHO itself uses the word “resurges” to describe the trend, and its 2024 global report confirmed that the disease returned to being the leading infectious disease killer in 2023, overtaking COVID-19. That framing suggests the agency views the numbers as reflecting genuine resurgence, not simply improved case-finding.
The demographic breakdown reinforces that concern. Among people who developed TB in 2023, 55% were men, 33% were women, and 12% were children and young adolescents. The share among children is particularly telling because pediatric TB cases typically indicate recent transmission in households and communities rather than reactivation of old infections. When children become ill, it often points to undiagnosed adults in their immediate environment, signaling gaps in community-level screening and preventive therapy.
These global figures also obscure wide disparities between and within countries. High-burden nations in Africa and Southeast Asia continue to account for a large share of cases, but pockets of vulnerability exist almost everywhere. Urban crowding, informal settlements, and prisons create ideal conditions for airborne transmission. In many places, health systems still rely on outdated diagnostic tools, meaning that even the record-high numbers likely underestimate the true scale of infection.
U.S. Cases Hit a 13-Year High
The trend is not confined to low- and middle-income countries. Provisional CDC data show that the United States reported 10,347 tuberculosis cases in 2024, a rate of 3.0 per 100,000 people. That represents an 8% increase from 2023 and the highest annual total since 2011. U.S. case counts and rates have been climbing since 2021, reversing a long downward trajectory that public health officials had treated as evidence the country was on track to eliminate the disease domestically.
The CDC attributes the increase to several converging forces: post-pandemic disruptions to screening and treatment programs, changes in international travel and migration, and localized outbreaks. During the COVID-19 emergency, many TB clinics reduced hours or closed temporarily, routine checkups were deferred, and patients hesitated to seek care. Those delays allowed latent infections to progress and active disease to spread unnoticed. The agency’s surveillance analysis for 2023 documented that non-U.S.-born individuals accounted for a substantial majority of reported cases, reflecting how TB circulates through global migration networks before appearing in domestic statistics.
One concrete example of how outbreaks drive local surges is the Kansas City area cluster, which the Kansas health department has been tracking across multiple counties. That investigation required rapid contact tracing, targeted testing in workplaces and congregate settings, and coordination with neighboring jurisdictions. TB remains a reportable condition with strict notification timelines, and molecular surveillance using whole-genome sequencing now helps health departments link cases into clusters. Yet that capacity depends on sustained funding and staffing that many local agencies have struggled to maintain after emergency COVID-19 funds expired.
Within the U.S., the burden falls unevenly. People born in countries where TB is more common, individuals experiencing homelessness, those living with HIV, and residents of long-term care or correctional facilities all face higher risk. Even so, experts emphasize that TB anywhere is a concern for public health everywhere: airborne bacteria do not respect borders, and underdiagnosed cases in one community can seed infections far beyond it.
Why Decades of Medical Progress Have Not Been Enough
Despite effective antibiotics that can cure most TB cases and a vaccine that has existed for over a century, the disease continues to kill on a massive scale. An estimated 1.23 million people died from tuberculosis in 2024, including 150,000 among people living with HIV, according to the WHO’s tuberculosis fact sheet. Peer-reviewed research published in early 2025 noted that TB remains a leading killer despite significant advancements in medical science and public health initiatives.
The gap between what medicine can do and what health systems actually deliver explains much of this failure. Standard TB treatment requires at least four antibiotics taken daily for months, with frequent follow-up visits and lab tests. For many patients, especially those in low-resource settings or precarious living situations, that level of adherence is difficult to sustain. Work obligations, transportation costs, stigma, and mistrust of health authorities all contribute to people dropping out before completing therapy.
When treatment is interrupted or improperly prescribed, drug-resistant strains can emerge. Multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) require longer, more toxic, and far more expensive regimens, often involving injectable drugs and close monitoring for side effects. These forms of TB are harder to cure and more likely to spread in hospitals and communities where infection control is weak. The WHO’s annual assessments, drawing on data from 184 countries and areas, consistently show that the nations with the highest burden of MDR-TB are also those with the least capacity to diagnose it quickly and provide appropriate care.
Prevention tools also have limits. The century-old Bacille Calmette-Guérin (BCG) vaccine offers some protection against severe TB in children but is much less effective at preventing pulmonary disease in adults, which is responsible for most transmission. New vaccine candidates are in development, but none are yet widely available. Meanwhile, preventive treatment for people with latent TB infection (those who carry the bacteria but are not sick) is underused in many high-burden settings because it requires screening resources and long courses of medication for people who feel healthy.
Funding Cuts Threaten Recent Gains
Even as case counts rise, the money available to fight TB is shrinking. The WHO warned in November 2025 that global gains in the tuberculosis response are endangered by funding challenges, with cuts to international donor support threatening to reverse progress. Officials have expressed concern that reduced investment will weaken core services such as case detection, laboratory networks, and treatment support programs just as demand for those services is increasing.
Many national TB programs rely heavily on external financing to purchase diagnostic tests, second-line drugs, and preventive therapies. When donors scale back, health ministries often struggle to fill the gap from domestic budgets that are already stretched by competing priorities, including noncommunicable diseases and lingering COVID-19 costs. The result can be stockouts of key medicines, delays in rolling out newer diagnostic tools, and hiring freezes that leave clinics understaffed.
Research and development face similar pressures. Promising vaccine candidates, shorter treatment regimens, and novel diagnostics all require sustained funding over many years to move from early trials to real-world use. WHO leaders have warned that without intensified research investment, the world risks being locked into the current toolkit (effective but imperfect) for another generation. That would make it far harder to bend the curve on incidence and mortality in line with global targets.
Advocates argue that the recent resurgence should be a wake-up call. They point out that TB control yields benefits beyond a single disease: stronger laboratory systems, better infection prevention in health facilities, and more robust community health networks all contribute to resilience against future outbreaks of other pathogens. Conversely, letting TB programs erode can create vulnerabilities that extend well beyond one bacterium.
For now, the data tell a clear story. After decades of slow but steady progress, tuberculosis is once again moving in the wrong direction, both globally and in countries that once saw it as a problem of the past. Reversing that trend will require not only maintaining current efforts but expanding them, finding and treating more people earlier, supporting patients through long courses of therapy, and investing in the next generation of tools. Whether governments and donors are willing to make that commitment will determine if TB remains the world’s deadliest infectious disease or finally begins to loosen its grip.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
